Loading patent…
AssigneeAdvanced Cell Diagnostics, Inc.
InventorsXIAO-JUN MA, Xingyong Wu, Yuling Luo
Estimating the term…
Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (PHACTR1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (SPP1), preferentially expressed antigen in melanoma (PRAME), growth differentiation factor 15 (GDF 15), and chemokine C-X-C motif ligand 10 (CXCL10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of PHACTR1, or fragments thereof, either alone or in combination with the detection of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.
A method for diagnosing melanoma in a human subject suspected of melanoma, comprising the following steps:
A method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, comprising the following steps:
A method for determining the stage of melanoma in a human subject, comprising the following steps:
A diagnostic kit, comprising at least one substance for detection of the level of expression of PHACTR1 gene, either alone or in combination with the detection of one or more genes selected from the group consisting of SPP1, PRAME, GDF15, and CXCL10, for the diagnosis or prognosis of melanoma.
Dependencies are inferred from the claim text.